
June 2023 FDA Watch
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
Lucira has fallen on hard times since it secured the first FDA EUA for an at-home COVID-19 test in November 2020.
COVID-19 test makers will either have to get full marketing approval, or take the product off the market.
On March 27, the agency released a new guidance document to help test developers make the transition to full approval.
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.